Sanofi, MyoKardia collaboration targets genetic heart disease

Sanofi and MyoKardia announced their worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease

slide1

(Photo Courtesy: www.heartregistry.org.au)

The collaboration provides up to $200 million in equity investments, milestone payments, and R&D services through 2018.

MyoKardia is a privately-held US-company, leading the development of precision therapies for genetic heart disease.

The collaboration builds upon MyoKardia's pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction.

The collaboration, representing one of the largest research and development commitments to genetic forms of cardiomyopathy, encompasses three MyoKardia programs.

Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM).

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X